KKR to Take Medical Device Maker Integer Holdings Private in $5.7 Billion All-Cash Deal

Deal Structure and Financial Terms

Under the terms of the agreement, KKR will acquire all outstanding shares of Integer for $127.00 per share in cash. This offer price represents a 51.8% premium to Integer’s closing price on April 29, 2026—the day prior to the company’s announcement of a formal strategic review—and a 28.8% premium over its 30-day volume-weighted average price (VWAP) as of July 31, 2026.

The acquisition has received unanimous approval from the Integer Board of Directors. The deal is expected to close by the end of 2026, subject to customary closing conditions, regulatory clearances, and the approval of Integer’s stockholders. Notably, the transaction is not subject to a financing contingency, with KKR utilizing equity from its managed funds and committed debt financing.

Strategic Rationale and Activist Catalyst

The path to this buyout was paved by activist engagement and a shifting competitive landscape. In early 2026, Irenic Capital Management, which holds a significant stake in Integer, pushed for a strategic review, leading to the appointment of two new directors to the board in March. Analysts from firms such as Goldman Sachs and Bain & Company have recently highlighted that scaled CDMOs like Integer are becoming increasingly attractive as “essential infrastructure” for original equipment manufacturers (OEMs) looking to de-risk their supply chains.

For KKR, the acquisition aligns with its strategy of investing in high-conviction healthcare verticals. Integer’s portfolio—spanning cardiac rhythm management, neuromodulation, and cardio-vascular components—provides KKR with a global platform characterized by high switching costs and durable customer relationships with the world’s leading medical device companies.

Operational Resilience Amidst Mixed Q2 Results

Coinciding with the deal announcement, Integer released its second-quarter 2026 financial results, which beat analyst expectations on the bottom line despite a slight contraction in top-line revenue. The company reported adjusted EPS of $1.60 (beating the $1.51 consensus) on revenue of $464 million.

Integer Performance Snapshot (Q2 2026)

Industry Implications: The 2026 Medtech M&A Landscape

The KKR-Integer deal is a bellwether for cross-border M&A trends in 2026, particularly within the healthcare technology and outsourcing sectors. As strategic buyers and private equity firms navigate a more favorable regulatory environment under a pro-business administration, “take-private” transactions for specialized manufacturers are resurging. This deal follows other high-profile moves, such as Blackstone and TPG’s $18 billion acquisition of Hologic and Boston Scientific’s acquisition of Penumbra.

Market observers note that private equity exit strategies in medtech are evolving; firms are increasingly focusing on platform-based technologies and supply chain ownership to insulate against reimbursement shifts. By taking Integer private, KKR provides the company with the capital flexibility to pursue further bolt-on acquisitions—a strategy Integer had already begun with its recent purchases of Precision Coating and VSi Parylene.

Leadership and Employment Impact

Integer President and CEO Payman Khales is expected to continue leading the organization through the transition. KKR has signaled a commitment to Integer’s 11,000 associates, often implementing broad-based employee ownership programs across its portfolio companies—a hallmark of KKR’s “Shared Success” model. While large-scale layoffs are not anticipated given the growth-oriented nature of the buyout, typical post-merger integrations may lead to some administrative consolidation as the company delists from the NYSE.

As of today’s announcement, Integer has withdrawn its full-year 2026 financial outlook and canceled its previously scheduled earnings conference call. The focus now shifts to the regulatory risks and closing timelines typical of a deal this size, though the lack of product overlap between KKR’s existing portfolio and Integer’s core manufacturing business suggests a smooth path through antitrust review.